Maricann Group Inc. announced the appointment of Scott Langille as the company's Chief Financial Officer effective October 2, 2017, subject to regulatory approval. Mr. Langille has over 30 years of experience in the pharmaceutical industry in both Canada and the United States. He was formerly Chief Financial Officer of Tribute Pharmaceuticals Canada Inc., which was sold to Pozen Inc. in February 2016 for USD 160 million to form Aralez Pharmaceuticals Inc.